Theranica

Theranica develops advanced, clinically proven, safe and affordable digital therapeutics, addressing some of the world’s most prevalent neurological pain diseases. Theranica is the developer of Nerivio, a fully integrated, self-contained family of therapeutic patches. The patches and other types of wearables in the companys pipeline are controlled by smartphone applications to easily adapt therapy treatments to everyday life. Nerivio Migra is a migraine-relief patch that provides migraine treatment through neuromodulation. Instead of placing electrodes on their head, patients can attach Theranicas clinically tested, wearable patch to their arm and launch a personalized pain-relief program. Theranica combines electrical neurostimulation and neuromuscular stimulation technologies with modern wireless communication and smartphone applications. The company uses these advanced technologies to design and deliver effective products for treating a variety of severe and common medical problems. In May 2019, Theranica won FDA De Novo clearance for its Nerivio Migra device. In June 2019, the company announced the establishment of a wholly owned subsidiary company, Theranica USA, headquartered in Montclair, New Jersey.

Theranica has raised $88.1M in total funding across 5 rounds. The company is currently at the C stage. Key investors include New Rhein Healthcare Investors, LionBird, Takoa.

Theranica was founded in 2015 by Alon Ironi (Co-founder, President & CEO), Ronen Jashek (Co-Founder, COO), Slava Barabash (Co-founder, VP R&D).

Theranica operates in Health Tech & Life Sciences, Digital Healthcare, Digital Therapeutics, with core technologies in Semiconductors & Electronics, Wearables, Platforms & Interfaces, Mobile. Target customers: Consumers, Demographics & Family, Women, Teenagers & Young Adults, Healthcare & Life Sciences, Healthcare, Patients.

Theranica is based in Ha-Omanut St 4, Netanya, Israel, Center District. The company also has offices abroad.